Table 4.
Summary of discordant cases between the OSNA assay and pathological ultrastaging.
| No. | Age | Histology | Tumor (mm) |
Grade | OSNA | CK19 mRNA (Copies/µL) | Ultrastaging | P-LA | PA-LA |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 61 | Endometrioid | 15 | G2 | (+) | 3500 | Negative | 0/20 | NP |
| 2 | 56 | Serous | 1 | G3 | (+) | 1500 | Negative | 1/17 | 0/12 |
| 3 | 60 | Endometrioid | 5 | G3 | (++) | 5620 | Negative | 2/14 | 3/19 |
| 4 | 61 | Endometrioid | 15 | G1 | (+) | 1270 | Negative | 0/7 | 0/5 |
| 5 | 71 | Endometrioid | 30 | G1 | (+) | 270 | Negative | 0/4 | 0/1 |
| 6 | 74 | Endometrioid | 50 | G2 | (−)L | 120 | Micromet | 0/23 | NP |
| 7 | 77 | Endometrioid | 40 | G2 | (++) | 18,950 | Negative | 0/9 | 0/24 |
| 8 | 53 | Endometrioid | 42 | G1 | (+) | 3100 | Negative | NP | NP |
| 9 | 52 | Endometrioid | 26 | G1 | (+) | 410 | Negative | NP | NP |
| 10 | 57 | Endometrioid | 33 | G1 | (−) | 0 | Micromet | 0/16 | 0/7 |
| 11 | 51 | Endometrioid | 40 | G1 | (+) | 560 | Negative | 0/6 | 0/15 |
| 12 | 34 | Endometrioid | 15 | G1 | (+) | 1630 | Negative | NP | NP |
| 13 | 75 | Endometrioid | 35 | G2 | (+) | 1600 | Negative | 0/7 | NP |
| 14 | 68 | Clear cell | NA | G3 | (+) | 1100 | Negative | NP | NP |
| 15 | 59 | Endometrioid | 23 | G1 | (+) | 3100 | Negative | 0/11 | NP |
| 16 | 69 | Endometrioid | 7 | G2 | (+) | 300 | Negative | 0/15 | NP |
| 17 | 48 | Endometrioid | 50 | G1 | (+) | 530 | Negative | 0/11 | NP |
| 18 | 67 | Endometrioid | 30 | G1 | (+) | 1580 | Negative | 0/5 | NP |
| 19 | 57 | Clear cell | 40 | G3 | (+) | 470 | Negative | NP | NP |
| 20 | 59 | Endometrioid | 32 | G1 | (+) | 960 | Negative | 0/2 | NP |
OSNA (qualitative result): (−), negative; (−)L, isolated tumor cells; (+), micrometastasis; (++), macrometastasis; P-LA, Pelvic lymphadenectomy; PA-LA, Para-aortic lymphadenectomy; NA, Not available; NP, Not performed.